DGAT2 and metabolic dysfunction-associated steatohepatitis: The results showed that ACC1 inhibitor alone had obvious inhibitory effect on NASH, but it could induce hyperlipidemia, while the combination with DGAT2 inhibitor could reduce the side effects.